Key result
Single-cell RNA sequencing dissects cellular heterogeneity and crosstalk in CAVD to identify novel therapeutic targets.
This review highlights the role of single-cell transcriptomics in unraveling the pathogenesis of calcific aortic valve disease and identifying novel therapeutic targets.
Does not alter calcific aortic valve disease management; leaves open whether scRNA-seq targets prove therapeutically actionable.
Single-cell RNA sequencing (scRNA-seq) has revolutionized the study of calcified aortic valve disease (CAVD) by enabling the dissection of cellular heterogeneity, lineage differentiation, and intercellular crosstalk at an unprecedented resolution. It revealed original vistas into the mechanisms of CAVD and novel putative therapeutic targets. This review provides a narrative state-of-the-art overview of scRNA-seq applications in CAVD research, summarizing key findings on valvular cell populations, disease-associated phenotypic transitions, and molecular pathways driving pathological remodeling. Additionally, the translational potential of single-cell technologies in identifying novel therapeutic targets is discussed, as well as the current challenges and future directions in this rapidly evolving field.
No takes yet. Share an insight, caveat, or question.
Qin et al. (2025) conducted a review in Calcified aortic valve disease (CAVD). Single-cell RNA sequencing (scRNA-seq) was evaluated. Single-cell RNA sequencing enables the dissection of cellular heterogeneity, lineage differentiation, and intercellular crosstalk in calcified aortic valve disease to identify novel therapeutic targets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: